Q4 2024 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2025-02-14 · accession 0001937964-25-000003
$279.8M
Reported value
37
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $22.2M | 7.94% | 494,424 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $19.5M | 6.97% | 463,840 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $18.4M | 6.56% | 219,719 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $17.6M | 6.30% | 229,785 | Common | SOLE |
| 670100205 | NVO | NOVO-NORDISK A S | $17.2M | 6.15% | 200,000 | Common | SOLE |
| 670100205 | NVO | NOVO-NORDISK A S | $17.2M | 6.15% | 200,000 | PUT | SOLE |
| 670703107 | NUVL | NUVALENT INC | $16.0M | 5.71% | 204,045 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $13.3M | 4.75% | 162,255 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $13.3M | 4.74% | 56,400 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $12.5M | 4.47% | 190,752 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $12.4M | 4.44% | 284,190 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $11.9M | 4.24% | 255,318 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $11.6M | 4.14% | 167,939 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $11.3M | 4.05% | 293,851 | Common | SOLE |
| 78464A870 | XBI | SPDR SER TR | $9.0M | 3.22% | 100,000 | PUT | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $8.7M | 3.12% | 162,976 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $7.0M | 2.49% | 11,311 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $6.1M | 2.20% | 45,000 | Common | SOLE |
| 670100205 | NVO | NOVO-NORDISK A S | $4.3M | 1.54% | 50,000 | CALL | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $3.6M | 1.30% | 90,279 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $2.8M | 1.00% | 50,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $2.3M | 0.84% | 45,765 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $2.3M | 0.83% | 102,900 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $1.9M | 0.70% | 53,930 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.9M | 0.69% | 100,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $1.6M | 0.59% | 54,515 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $1.6M | 0.58% | 216,700 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $1.6M | 0.56% | 40,000 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $1.5M | 0.53% | 421,359 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $1.4M | 0.50% | 54,285 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $1.3M | 0.48% | 80,380 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $1.3M | 0.48% | 50,000 | PUT | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $1.2M | 0.42% | 6,305 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $1.2M | 0.41% | 20,811 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $1.0M | 0.37% | 7,440 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $883,519 | 0.32% | 172,226 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $768,731 | 0.27% | 16,650 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.